Table 5.
Individual miRNAs and their significance across the different disease group comparisons in the discovery study
| miRNA | Significant sALS comparisons (p value) |
|||||
|---|---|---|---|---|---|---|
| ALS v Con | ALS v Non Inflam | ALS v Struct | ALS v Myop | ALS v Inflam | ALS v MG | |
| hsa-miR-133a-3p | 0.021 | 0.010 | ||||
| hsa-miR-135b-5p | 0.045 | |||||
| hsa-miR-143-3p | 0.021 | 0.030 | 0.037 | 0.008 | ||
| hsa-miR-144-3p | 0.014 | 0.014 | 0.023 | |||
| hsa-miR-146b-3p | 0.042 | |||||
| hsa-miR-206 | 0.000 | |||||
| hsa-miR-20a-3p | 0.003 | 0.008 | ||||
| hsa-miR-214-3p | 0.041 | |||||
| hsa-miR-331-3p | 0.033 | |||||
| hsa-miR-374b-5p | 0.025 | |||||
| hsa-miR-518d-3p | 0.035 | |||||
| hsa-miR-551b-3p | 0.049 | |||||
| hsa-let-7d-5p | 0.018 | 0.011 | ||||
| hsa-miR-106b-5p | 0.031 | 0.033 | ||||
| hsa-miR-133b | 0.020 | 0.020 | ||||
| hsa-miR-134-5p | 0.034 | 0.004 | ||||
| hsa-miR-145-3p | 0.002 | 0.020 | ||||
| hsa-miR-15b-5p | 0.021 | 0.045 | ||||
| hsa-miR-190a-5p | 0.019 | 0.026 | ||||
| hsa-miR-196b-5p | 0.008 | 0.040 | ||||
| hsa-miR-301a-3p | 0.017 | 0.018 | ||||
| hsa-miR-335-5p | 0.049 | 0.028 | 0.014 | |||
| hsa-miR-381-3p | 0.050 | 0.020 | ||||
| hsa-miR-500a-3p | 0.023 | 0.032 | ||||
| hsa-miR-532-3p | 0.045 | 0.048 | ||||
| hsa-miR-744-5p | 0.029 | 0.039 | ||||
| miRNA | Significant comparisons (p value) |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Con v Non Inflam | Con v Struct | Con v Myop | Con v Inflam | Con v MG | Non Inflam v Struct | Inflam v Non Inflam | Inflam v Struct | Inflam v Myop | Inflam v MG | Myop v Non Inflam | Myop v Struct | MG v Struct | MG v Myop | |
| hsa-miR-133a-3p | 0.028 | |||||||||||||
| hsa-miR-135b-5p | 0.011 | 0.029 | ||||||||||||
| hsa-miR-144-3p | 0.041 | |||||||||||||
| hsa-miR-206 | 0.002 | |||||||||||||
| hsa-miR-20a-3p | 0.017 | 0.048 | ||||||||||||
| hsa-miR-214-3p | 0.017 | |||||||||||||
| hsa-miR-331-3p | 0.024 | |||||||||||||
| hsa-miR-374b-5p | 0.005 | |||||||||||||
| hsa-miR-1 | 0.012 | 0.008 | 0.039 | |||||||||||
| hsa-let-7d-5p | 0.049 | 0.022 | 0.017 | |||||||||||
| hsa-miR-106b-5p | 0.021 | 0.023 | ||||||||||||
| hsa-miR-133b | 0.025 | |||||||||||||
| hsa-miR-134-5p | 0.030 | 0.032 | 0.043 | |||||||||||
| hsa-miR-145-3p | 0.010 | 0.029 | 0.022 | |||||||||||
| hsa-miR-15b-5p | ||||||||||||||
| hsa-miR-190a-5p | 0.026 | 0.013 | 0.003 | 0.049 | 0.016 | 0.043 | ||||||||
| hsa-miR-196b-5p | 0.000 | 0.000 | 0.020 | 0.013 | ||||||||||
| hsa-miR-301a-3p | 0.024 | 0.020 | 0.039 | 0.045 | 0.032 | |||||||||
| hsa-miR-335-5p | 0.043 | 0.000 | 0.046 | 0.028 | 0.002 | 0.016 | ||||||||
| hsa-miR-381-3p | 0.034 | |||||||||||||
For each miRNA the number of comparisons is shown and the significance of each.
Key: ALS, amyotrophic lateral sclerosis patient group; Con, control subject group; Inflam, inflammatory neuropathy patient group; MG, myasthenia gravis patient group; miRNA, microRNA; Myop, myopathy patient group; n/a, data not applicable; NonInflam, noninflammatory neuropathy patient group; Struct, structural spinal disorders patient group; v, versus.